Unravelling the Molecular Identification and Antifungal Susceptibility Profiles of Aspergillus spp. Isolated from Chronic Pulmonary Aspergillosis Patients in Jakarta, Indonesia: The Emergence of Cryptic Species

Zaini, Jamal; Abdullah, Asriyani; Setianingrum, Findra; Sjamsuridzal, Wellyzar; Wahyuningsih, Retno; Bowolaksono, Anom; Fatril, Ayu Eka; Adawiyah, Robiatul; Tugiran, Mulyati; Syam, Ridhawati; Kartika, Rona; Kosmidis, Chris; Denning, David W.

doi:10.3390/jof8040411

Cited by 6 publications

(4 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 34 – 43 Reports from Indonesia indicate that cryptic species were identified in 24% of patients with CPA, emphasizing the need for accurate identification. 44 Matrix-assisted laser desorption ionization coupled to time-of-flight mass spectrometry (MALDI-TOF/MS) is increasingly being used for identification, and some closely related species can now be identified. 45 , 46 However, we have experienced a case in which A. udagawae was misidentified as A. thermomutatus because it was not registered in the MALDI-TOF/MS database, 47 and we believe that genetic identification is still necessary to determine the exact species.…”

Section: Aspergillosis-causing Fungimentioning

confidence: 99%

Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges

Tashiro,

Takazono,

Izumikawa

2024

Therapeutic Advances in Infection

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) is a challenging respiratory infection caused by the environmental fungus Aspergillus. CPA has a poor prognosis, with reported 1-year mortality rates ranging from 7% to 32% and 5-year mortality rates ranging from 38% to 52%. A comprehensive understanding of the pathogen, pathophysiology, risk factors, diagnosis, surgery, hemoptysis treatment, pharmacological therapy, and prognosis is essential to manage CPA effectively. In particular, Aspergillus drug resistance and cryptic species pose significant challenges. CPA lacks tissue invasion and has specific features such as aspergilloma. The most critical risk factor for the development of CPA is pulmonary cavitation. Diagnostic approaches vary by CPA subtype, with computed tomography (CT) imaging and Aspergillus IgG antibodies being key. Treatment strategies include surgery, hemoptysis management, and antifungal therapy. Surgery is the curative option. However, reported postoperative mortality rates range from 0% to 5% and complications range from 11% to 63%. Simple aspergilloma generally has a low postoperative mortality rate, making surgery the first choice. Hemoptysis, observed in 50% of CPA patients, is a significant symptom and can be life-threatening. Bronchial artery embolization achieves hemostasis in 64% to 100% of cases, but 50% experience recurrent hemoptysis. The efficacy of antifungal therapy for CPA varies, with itraconazole reported to be 43–76%, voriconazole 32–80%, posaconazole 44–61%, isavuconazole 82.7%, echinocandins 42–77%, and liposomal amphotericin B 52–73%. Combinatorial treatments such as bronchoscopic triazole administration, inhalation, or direct injection of amphotericin B at the site of infection also show efficacy. A treatment duration of more than 6 months is recommended, with better efficacy reported for periods of more than 1 year. In anticipation of improvements in CPA management, ongoing advances in basic and clinical research are expected to contribute to the future of CPA management.

show abstract

Section: Aspergillosis-causing Fungimentioning

confidence: 99%

Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges

Tashiro,

Takazono,

Izumikawa

2024

Therapeutic Advances in Infection

View full text Add to dashboard Cite

show abstract

“…brunneoviolaceus thrives in a variety of environments. This fungus has previously been isolated from food, soil, water, plants, animal droppings, industrial material, indoor air environment, corneal scrapings, and human sputum (Rozaliyani et al, 2022;Mistry et al, 2021;Ezekiel et al, 2020a;Ezekiel et al, 2020b;Jurjević et al, 2012;Varga et al 2011).…”

Section: Jcbr Vol 2 Is 4 July-august 2022mentioning

confidence: 99%

In vitro Antimicrobial Activity of Secondary Metabolites of an Endophytic Aspergillus brunneoviolaceus Isolated from Bryophyllum pinnatum (Lam.) Oken

Okonkwo-Uzor

Okezie

Eze

et al. 2022

jcbr

View full text Add to dashboard Cite

The antimicrobial properties of secondary metabolites produced by the endophytic Aspergillus brunneoviolaceus associated with the Nigerian plant Bryophyllum pinnatum were investigated in this study. Standard procedures were followed for fungal isolation and identification, as well as fermentation and extraction of fungal secondary metabolites. The agar-well diffusion method was used to assess the antimicrobial activity of the fungal extract. At 1 mg/mL, the fungal extract demonstrated broad spectrum antibacterial activity against the test bacteria (Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Bacillus subtilis), with inhibition zone diameters (IZD) ranging from 14 to 16 mm. The extract also exhibited antifungal activity with an IZD of 16 mm produced against Candida albicans. The findings of this study indicate that endophytic A. brunneoviolaceus associated with B. pinnatum has the potential to be a promising source of novel antimicrobial compounds with pharmaceutical importance.

show abstract

“…The main cause of IPA is A. fumigatus (with 57%), while other species, such as A. flavus , A. niger and A. terreus were found in about 12%, 10% and 12% of the cases, respectively, although these numbers can vary between countries [ 4 ]. In addition, infections with cryptic species of Aspergillus have been increasingly identified in clinical settings in the last few decades [ 9 , 10 , 11 , 12 , 13 ]. What is more, Aspergilli reside on crops such as nuts, grains, beans, and dried fruits, which leads to spoilage [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Novel Treatment Approach for Aspergilloses by Targeting Germination

Verburg

Neer

Duca

et al. 2022

JoF

View full text Add to dashboard Cite

Germination of conidia is an essential process within the Aspergillus life cycle and plays a major role during the infection of hosts. Conidia are able to avoid detection by the majority of leukocytes when dormant. Germination can cause severe health problems, specifically in immunocompromised people. Aspergillosis is most often caused by Aspergillus fumigatus (A. fumigatus) and affects neutropenic patients, as well as people with cystic fibrosis (CF). These patients are often unable to effectively detect and clear the conidia or hyphae and can develop chronic non-invasive and/or invasive infections or allergic inflammatory responses. Current treatments with (tri)azoles can be very effective to combat a variety of fungal infections. However, resistance against current azoles has emerged and has been increasing since 1998. As a consequence, patients infected with resistant A. fumigatus have a reported mortality rate of 88% to 100%. Especially with the growing number of patients that harbor azole-resistant Aspergilli, novel antifungals could provide an alternative. Aspergilloses differ in defining characteristics, but germination of conidia is one of the few common denominators. By specifically targeting conidial germination with novel antifungals, early intervention might be possible. In this review, we propose several morphotypes to disrupt conidial germination, as well as potential targets. Hopefully, new antifungals against such targets could contribute to disturbing the ability of Aspergilli to germinate and grow, resulting in a decreased fungal burden on patients.

show abstract

Unravelling the Molecular Identification and Antifungal Susceptibility Profiles of Aspergillus spp. Isolated from Chronic Pulmonary Aspergillosis Patients in Jakarta, Indonesia: The Emergence of Cryptic Species

Cited by 6 publications

References 65 publications

Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges

Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges

In vitro Antimicrobial Activity of Secondary Metabolites of an Endophytic Aspergillus brunneoviolaceus Isolated from Bryophyllum pinnatum (Lam.) Oken

Novel Treatment Approach for Aspergilloses by Targeting Germination

Contact Info

Product

Resources

About